Edison J Cano1,2, Katherine M Caflisch2,3, Paul L Bollyky4, Jonas D Van Belleghem4, Robin Patel1,2,5, Joseph Fackler6, Michael J Brownstein6, Bri'Anna Horne6, Biswajit Biswas7, Matthew Henry7,8, Francisco Malagon7, David G Lewallen9, Gina A Suh1. 1. Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA. 2. Infectious Diseases Research Laboratory, Mayo Clinic, Rochester, Minnesota, USA. 3. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA. 4. Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 5. Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA. 6. Adaptive Phage Therapeutics, Gaithersburg, Maryland, USA. 7. Genomics and Bioinformatics Department, Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Fort Detrick, Maryland, USA. 8. Geneva Foundation, Tacoma, Washington, USA. 9. Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
BACKGROUND: Prosthetic joint infection (PJI) is a potentially limb-threatening complication of total knee arthroplasty. Phage therapy is a promising strategy to manage such infections including those involving antibiotic-resistant microbes, and to target microbial biofilms. Experience with phage therapy for infections associated with retained hardware is limited. A 62-year-old diabetic man with a history of right total knee arthroplasty 11 years prior who had suffered multiple episodes of prosthetic knee infection despite numerous surgeries and prolonged courses of antibiotics, with progressive clinical worsening and development of severe allergies to antibiotics, had been offered limb amputation for persistent right prosthetic knee infection due to Klebsiella pneumoniae complex. Intravenous phage therapy was initiated as a limb-salvaging intervention. METHODS: The patient received 40 intravenous doses of a single phage (KpJH46Φ2) targeting his bacterial isolate, alongside continued minocycline (which he had been receiving when he developed increasing pain, swelling, and erythema prior to initiation of phage therapy). Serial cytokine and biomarker measurements were performed before, during, and after treatment. The in vitro anti-biofilm activity of KpJH46Φ2, minocycline and the combination thereof was evaluated against a preformed biofilm of the patient's isolate and determined by safranin staining. RESULTS: Phage therapy resulted in resolution of local symptoms and signs of infection and recovery of function. The patient did not experience treatment-related adverse effects and remained asymptomatic 34 weeks after completing treatment while still receiving minocycline. A trend in biofilm biomass reduction was noted 22 hours after exposure to KpJH46Φ2 (P = .063). The addition of phage was associated with a satisfactory outcome in this case of intractable biofilm-associated prosthetic knee infection. Pending further studies to assess its efficacy and safety, phage therapy holds promise for treatment of device-associated infections.
BACKGROUND: Prosthetic joint infection (PJI) is a potentially limb-threatening complication of total knee arthroplasty. Phage therapy is a promising strategy to manage such infections including those involving antibiotic-resistant microbes, and to target microbial biofilms. Experience with phage therapy for infections associated with retained hardware is limited. A 62-year-old diabetic man with a history of right total knee arthroplasty 11 years prior who had suffered multiple episodes of prosthetic knee infection despite numerous surgeries and prolonged courses of antibiotics, with progressive clinical worsening and development of severe allergies to antibiotics, had been offered limb amputation for persistent right prosthetic knee infection due to Klebsiella pneumoniae complex. Intravenous phage therapy was initiated as a limb-salvaging intervention. METHODS: The patient received 40 intravenous doses of a single phage (KpJH46Φ2) targeting his bacterial isolate, alongside continued minocycline (which he had been receiving when he developed increasing pain, swelling, and erythema prior to initiation of phage therapy). Serial cytokine and biomarker measurements were performed before, during, and after treatment. The in vitro anti-biofilm activity of KpJH46Φ2, minocycline and the combination thereof was evaluated against a preformed biofilm of the patient's isolate and determined by safranin staining. RESULTS: Phage therapy resulted in resolution of local symptoms and signs of infection and recovery of function. The patient did not experience treatment-related adverse effects and remained asymptomatic 34 weeks after completing treatment while still receiving minocycline. A trend in biofilm biomass reduction was noted 22 hours after exposure to KpJH46Φ2 (P = .063). The addition of phage was associated with a satisfactory outcome in this case of intractable biofilm-associated prosthetic knee infection. Pending further studies to assess its efficacy and safety, phage therapy holds promise for treatment of device-associated infections.
Authors: Marzanna Łusiak-Szelachowska; Maciej Żaczek; Beata Weber-Dąbrowska; Ryszard Międzybrodzki; Sławomir Letkiewicz; Wojciech Fortuna; Paweł Rogóż; Krzysztof Szufnarowski; Ewa Jończyk-Matysiak; Ewa Olchawa; Kinga M Walaszek; Andrzej Górski Journal: Future Microbiol Date: 2016-09-19 Impact factor: 3.165
Authors: Hannah M Wolford; Kelly M Hatfield; Prabasaj Paul; Sarah H Yi; Rachel B Slayton Journal: Infect Control Hosp Epidemiol Date: 2018-08-30 Impact factor: 3.254
Authors: Marzanna Łusiak-Szelachowska; Maciej Zaczek; Beata Weber-Dąbrowska; Ryszard Międzybrodzki; Marlena Kłak; Wojciech Fortuna; Sławomir Letkiewicz; Paweł Rogóż; Krzysztof Szufnarowski; Ewa Jończyk-Matysiak; Barbara Owczarek; Andrzej Górski Journal: Viral Immunol Date: 2014-06-03 Impact factor: 2.257
Authors: Maciej Żaczek; Marzanna Łusiak-Szelachowska; Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska; Ryszard Międzybrodzki; Barbara Owczarek; Agnieszka Kopciuch; Wojciech Fortuna; Paweł Rogóż; Andrzej Górski Journal: Front Microbiol Date: 2016-10-24 Impact factor: 5.640
Authors: Gregory S Canfield; Anushila Chatterjee; Juliel Espinosa; Mihnea R Mangalea; Emma K Sheriff; Micah Keidan; Sara W McBride; Bruce D McCollister; Howard C Hang; Breck A Duerkop Journal: Antimicrob Agents Chemother Date: 2021-03-01 Impact factor: 5.191
Authors: Ishan Kamat; Harveen Lamba; Casey Hines-Munson; Samuel Hudson; Kenneth Liao; Kenneth L Muldrew; Sabrina Green; Austen Terwilliger; Heidi B Kaplan; Robert F Ramig; Anthony Maresso; Barbara W Trautner Journal: J Surg Res Date: 2021-11-27 Impact factor: 2.417
Authors: Claudia Ramirez-Sanchez; Francis Gonzales; Maureen Buckley; Biswajit Biswas; Matthew Henry; Michael V Deschenes; Bri'Anna Horne; Joseph Fackler; Michael J Brownstein; Robert T Schooley; Saima Aslam Journal: Viruses Date: 2021-06-21 Impact factor: 5.048